CWM
VRTX icon

Centricity Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Centricity Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$62.8K Hold
141
– – 0.05% 147
2025
Q1 		$68.4K Hold
141
– – 0.06% 137
2024
Q4 		$56.8K Buy
+141
New +$65.4K 0.05% 152

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Centricity Wealth Management's VRTX Position: Q2 2025 in Review

Centricity Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2025 at 141 shares worth $62.8K. The position accounts for 0.05% of the portfolio, ranked #147.

Centricity Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 3 quarters since. The position peaked at $68.4K in Q1 2025. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Centricity Wealth Management held 141 shares of Vertex Pharmaceuticals worth $62.8K as of Q2 2025.
  • Centricity Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2025.
  • Vertex Pharmaceuticals made up 0.05% of Centricity Wealth Management's portfolio in Q2 2025, its #147 holding.
  • Centricity Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Centricity Wealth Management's Vertex Pharmaceuticals position peaked at $68.4K in Q1 2025.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Centricity Wealth Management's 13F filing for Q2 2025, filed 18 Jul 2025.